

INVENTING NEW MEDICINES WITH TARGETED PROTEIN DEGRADATION



July 2021


Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. These statements include information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of historical facts contained in this presentation, including express or implied statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "positioned," "potential," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include statements about the initiation, timing, progress and results of our future clinical trials and current and future preclinical studies of our product candidates and of our research and development programs; our plans to develop and commercialize our current product candidates and any future product candidates and the implementation of our business model and strategic plans for our business, current product candidates and any future product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. You should not rely upon forward-looking statements as predictions of future events.

Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, the occurrence of certain events or otherwise. As a result of these risks and others, including those set forth in our most recent and future filings with the Securities and Exchange Commission, actual results could vary significantly from those anticipated in this presentation, and our financial condition and results of operations could be materially adversely affected. This presentation contains trademarks, trade names and service marks of other companies, which are the property of their respective owners.

Certain information contained in this presentation and statements made orally during this presentation relate to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party studies, publications, surveys and other data to be reliable as of the date of the presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent sources has evaluated the reasonableness or accuracy of the Company's internal estimates or research and no reliance should be made on any information or statements made in this presentation relating to or based on such internal estimates and research.


Kymera: A Leading TPD Company



WELL-POSITIONED

\$647M cash balance*

Kymera's Pipeline of Novel Protein Degraders



KYMERA ©2021 KYMERA THERAPEUTICS, INC.

Near-Term Milestones Provide Significant Opportunity


Program	Compound	Indication(s)	Expected Upcoming Milestones		
IRAK4	KT-474	AD, HS, RA, others	 Initiated SAD portion of Phase 1 trial in healthy volunteers (Feb 2021) Established degrader proof-of-mechanism in healthy volunteer SAD portion of Phase 1 trial (June 2021) Initiate enrollment in MAD portion of Phase 1 trial (July 2021) Present data from atopic dermatitis cohort in non-interventional study (2H21) Establish Phase 1 proof-of-biology in healthy volunteers (4Q21) and in patient cohort (1H22) 		
IRAKIMiD (IRAK4, Ikaros, Aiolos)	КТ-413	MYD88 ^{MT} DLBCL	 Presentation of preclinical data updates at AACR, ICML meetings (2Q21) Submit IND to initiate Phase 1 clinical trial in r/r B cell lymphomas (2H21) Present additional KT-413 preclinical data and potential expansion strategies (2H21) Establish Phase 1 proof-of-biology in patients (2022) Establish Phase 1 initial clinical proof-of-concept in patients (2022) 		
STAT3	KT-333	Liquid & Solid Tumors	 Nominated development candidate for liquid & solid tumor indications (1Q21) Present additional preclinical data in liquid & solid tumor indications (2H21) Submit IND to initiate Phase 1 clinical trial in liquid and solid tumors (4Q21) Establish Phase 1 proof-of-biology in patients (2022) Establish Phase 1 initial clinical proof-of-concept in patients (2022) 		
Discovery Programs & Platform		Platform	 Continue pipeline expansion by advancing early-stage discovery programs toward IND-enabling studies Further expand Pegasus platform to generate novel degrader product candidates Leverage Whole-Body Atlas to unlock new opportunities across broad therapeutic applications 		
= Oncold	ogy 🛑 = Immunolog	y-Inflammation			
K Y M E R A	©2021 KYMERA THE	RAPEUTICS, INC.	PAGE 5		

Pegasus[™] TPD Platform



Targeted Protein Degradation


Biology



KYMERA ©2021 KYMERA THERAPEUTICS, INC.

Targeted Protein Degradation

Next Potential Breakthrough Modality to Expand Drugged Proteome



Proprietary PegasusTM TPD Platform Key capabilities



- E3 ligase Whole-Body Atlas: Identification of the expression profiles of ~600 unique E3 ligases
- Match target protein with appropriate E3 ligase based on expression, distribution, intracellular localization, and biology
- **Toolbox of proprietary ligands** leverages the E3 Ligase Whole-Body Atlas



- Jnderstanding degradation PK/PD) across tissue types
- Ternary complex modeling tool optimizes the development of highly efficient and selective degrader therapeutics
 - Quantitative System Pharmacology Model measures and predicts diverse sets of parameters that impact protein levels
 - Based on understanding of PK/PD, both in vitro and in vivo, and across different tissues and cell types



- **Comprehensive hit finding technologies toolbox**: chemoproteomics, DEL, fragment screens, *in silico*
- Proprietary chemistry expertise enables the design and optimization of both E3 ligases and target protein binders
- Ability to convert into degraders with optimal pharmaceutical properties tailored to specific patient populations

V Pegasus: E3 Ligase Whole-Body Atlas

Different expression profiles of E3's provide opportunity for tissue selective/restricted degradation




Understanding degradation (PK/PD) across tissue types



Proprietary Chemistry


- Focused on determining the expression profiles of ~600 unique E3 ligases
- Patterns mapped in both disease and healthy contexts
- Ability to match a target protein with appropriate
 E3 ligase based on expression and biology
- Vision to develop tissueselective or tissuerestricted degraders to enable novel therapeutic opportunities



IRAK4 Degrader KT-474



IRAK4 Targeting: Clinical Validation, Human Genetics De-risking and **Degrader Advantage**



Clinical Pathway Validation

IL1-R\alpha/IL-1\beta: Rheumatologic Diseases **IL-1α:** Atopic Dermatitis IL-18: CANTOS Data, Atherosclerosis, Lung Cancer **IL-18:** Macrophage Activation Syndrome **IL-36:** Generalized Pustular Psoriasis **IRAK4 SMI:** Rheumatoid Arthritis

KYMERA ©2021 KYMERA THERAPEUTICS, INC.

KT-474 Opportunity

Immune-inflammatory disorders collectively impacting millions of patients in the U.S.

Atopic **Dermatitis (AD)**

Rheumatoid Arthritis (RA)

Hidradenitis Suppurativa (HS)

Additional Opportunities

KYMERA


Total Prevalence (U.S.) >16.0M¹ >1.3M² >325K ©2021 KYMERA THERAPEUTICS, INC.

- Chronic, pruritic inflammatory skin disease
- Large unmet need for safe and effective oral agents for patients with AD
- Chronic, systemic **autoimmune disease** that can cause irreversible joint damage
- Multiple therapies targeting the **IL-1R/TLR pathway** are approved
- Chronic and debilitating inflammatory skin disease
- ~25% of patients with moderate-to-severe disease⁴
- Adalimumab is approved, which provides some benefit to ~50% of patients with moderate-to-severe disease⁵
- Immune-inflammatory diseases impacted by IL-1R/TLR pathway

 Chiesa Fuxench et al. J Invest Dermatol. 2019 Mar;139(3):583-590. 2. Hunter et al. Rheumatol Int . 2017 Sep;37(9):1551-1557 3. Garg et al. JAMA Dermatol. 2017;153(8):760-764.

KT-474: Potent and Specific IRAK4 Degradation Superior to Kinase Inhibition


Degradation and Selectivity



Protein Level Fold Change (log2)

- KT-474 DC₅₀ = 2.1 nM in human immune cells
- KT-474 only degraded IRAK4 in human immune cells at concentration 10fold above the DC₉₀
- KT-474 better able to inhibit IL-6 under both LPS and LPS + IL-1B than clinically active IRAK4 SM kinase inhibitor PF-06550833


Superiority over SM kinase Inhibitor




Legend	Compound	IL-6 IC ₅₀ (nM)
	IRAK4 Degrader	0.8
	Negative control	450
	IRAK4 SMI (PF-06550833)	N/A

85% IRAK4 Degradation Sufficient for Maximal *In Vivo* Efficacy in Preclinical Models

- Ability to inhibit topical skin thickening induced by imiquimod was measured in a mouse model of psoriasis
- Orally dosed KT-474 inhibited thickening, a reflection of local and systemic inflammation, comparable to a topic corticosteroid after 2 or 4 days of dosing
- Full efficacy at doses achieving at 65-80% IRAK4 reduction in skin and spleen. In other models KT-474 has demonstrated full efficacy with 85% degradation





KT-474 in Dog: Multi-dosing Required to Achieve Target Degradation

- Orally-administered KT-474 achieves >85% knockdown of IRAK4 at Day 7 with repeat dosing in MAD study
- Multiple doses (MAD) lead to optimal degradation profile vs SAD upon reaching steady-state
- Consistency of IRAK4 knockdown observed across peripheral blood mononuclear cells (PBMC) and skin tissue

Dog Single Ascending Dose (SAD) IRAK4 Knockdown at Day 1

100 100 PBMC PBMC 90 90 Skin Skin 80 80 % IRAK4 Remaining % **IRAK4** Remaining 70 70 60 60 50 50 40 40 30 30 85% 85% 20 20 Reduction Reduction 10 10 0 0 3.0 0.3 1.0 10.0 0.3 1.0 3.0 10.0 Dose (mg/kg) Dose (mg/kg)

= Below Limit of Quantitation

Dog Multiple Ascending Dose (MAD)

IRAK4 Knockdown at Day 7


KT-474 Interim Phase 1 SAD Results



KT-474 Phase 1 Trial Design

Double-blind, Placebo-controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) trial

Three-part Phase 1 Design



Endpoints

• Safety & tolerability

Secondary/ Exploratory SAD & MAD

Exploratory

MAD only

- Pharmacokinetic measures (half-life, bioavailability)
- IRAK4 knockdown in PBMC
- IRAK4 knockdown in skin biopsies
- Proinflammatory cytokine and chemokine levels in skin biopsies
- C-reactive protein and cytokine levels in plasma
- Ex vivo response of whole blood to TLR agonists and IL-1 β

KT-474 Phase 1 Trial Goals

Establishing proof-of-mechanism and proof-of-biology

De-risking Milestones



Oral Bioavailability and Proof-of-Mechanism

- Efficacious plasma exposures that are safe and well-tolerated
- Proof-of-mechanism with IRAK4 knockdown following single KT-474 dose
- Predictable PK/PD supporting oral daily dosing regimen



Optimal IRAK4 Reduction and Proof-of-Biology


- ≥85% IRAK4 knockdown in skin and blood with daily dosing x 14 days that is safe and well-tolerated
- Proof-of-biology with systemic antiinflammatory effect: reduction in plasma hsCRP and inhibition of whole blood *ex* vivo response to TLR agonists and IL-1β
- Establishment of maximum effective dose




Establish Proof-of-Biology in Patients

- ≥85% IRAK4 degradation in diseased skin and blood
- Anti-inflammatory effect in diseased skin and reduction of plasma cytokines and hsCRP
- Confirmation of dose for subsequent Phase 2 studies

KT-474 Interim Phase 1 Healthy Volunteer SAD Overview



KT-474 Achieved Profound IRAK4 Degradation after Single Oral Dose that Lasted for at Least 6 Days




BLQ = Below Limit of Quantitation

* SAD4 144/312 h PD timepoints pending

- Measured by mass spectrometry in circulating PBMC
- IRAK4 levels nadired at 48-72 hours
- IRAK4 reduction lasted for at least 144h (6 days post-dose) in all dose groups

IRAK4 Degradation >85% Achieved Following Single KT-474 Dose



Percent IRAK4 Reduction in PBMC at 48 Hours Post-Dose using Mass Spectrometry

	Placebo (n=8)	Cohort 1 (n=6)	Cohort 2 (n=6)	Cohort 3 (n=6)	Cohort 4 (n=6)
KT-474 dose	-	25 mg	75 mg	150 mg	300 mg
Mean IRAK4 Change	+3%	-38%	-71%	-78%	-84%
Median IRAK4 Change	+16%	-41%	-71%	-78%	-90%
p value*		0.0057	<0.0001	<0.0001	<0.0001

* p-values relative to placebo

Interim Results from Phase 1 Healthy Volunteer SAD

Summary and Next Steps

KT-474 interim Phase 1 results demonstrate degrader proof-of-mechanism, first time for TPD in a placebo-controlled study

- Median IRAK4 reduction of 90% (p<0.0001 vs placebo) and maximum reduction of 94% at 48 hours following single dose of 300 mg, with sustained degradation that lasted for at least 6 days at all dose levels
- Based on potency, PK and PD profiles with deep and sustained multiday degradation, expect to achieve biologically relevant (85%) level of degradation with repeat dosing at lower doses; selected MAD starting dose of 25 mg
- Demonstrated predictable, dose-dependent and biologically active plasma exposures, and half-life that supports oral daily dosing
- No treatment-related adverse events or serious adverse events observed to date
- Demonstrating Phase 1 target degradation of >85% de-risks KT-474 ability to reach clinically relevant biological effects in future development as a potential best-in-class anti-inflammatory oral drug


• FDA lifted partial clinical hold following review of interim healthy volunteer SAD results

- Dose escalation in SAD portion of Phase 1 to continue, including assessment of food-effect
- In July, plan to initiate MAD portion of Phase 1 in healthy volunteers assessing daily dosing of KT-474 for 14 days

Expect to present updated results from healthy volunteer SAD/MAD portions in Q4'21

- Data to include IRAK4 degradation in skin and PBMC and effects on inflammatory biomarkers after repeat dosing
- Optimal dose from MAD healthy volunteer portion to be evaluated in an open label cohort of patients with atopic dermatitis and hidradenitis suppurativa

KT-474 Development Plan



IRAKIMID




IRAKIMID A combo in a single molecule

- MYD88 mutation drives differentiation and proliferation in ~25% of diffuse large B cell lymphoma (DLBCL)
- IMiDs downregulate IRF4, increasing IFN signaling and further suppressing NFkB activation and show activity in lymphoma
- Inhibiting both MYD88 and IRF4-dependent NFkB and activating IFN signaling drive cell death in MYD88-mutant lymphomas and leads to full and durable responses *in vivo*
- Combining two therapeutically relevant pathways in a single molecule has the potential to be first single agent targeted therapy agent in lymphoma (MYD88-mut)

Indications/Expected Timeline

MYD88-mutant DLBCL

Current: KT-413 in IND-enabling activities IND/Phase 1 initiation: 2H 2021 Phase 1 proof-of-biology in patients: 2022



IRAK4 + Ikaros/Aiolos

KT-413 Opportunity

Potential to be first precision medicine in DLBCL to target a genetically defined population (MYD88-mut)

MYD88-mutant DLBCL

Other MYD88-mutant **B** cell Lymphomas

> Additional Cancers

KYMERA



Patient Impact (U.S.)

per year

>1.0k[°]

per year

• MYD88 is mutated in at least 25% of DLBCL patients, the most common subtype of non-Hodgkin's lymphoma¹

Front-line treatment includes R-CHOP (chemo/rituximab)

 DLBCL 5-year survival rate is ~64%, and MYD88 mutations in DLBCL are associated with poorer survival following frontline R-CHOP chemotherapy³

 MYD88 is mutated in approximately 90% of Waldenström's macroglobulinemia cases and 70% of primary central nervous system lymphoma^{4,5}

©2021 KYMERA THERAPEUTICS, INC.




• **IL1R/TLR/NF**κ**B**-driven cancers, AML & MDS subsets with long isoform of IRAK4 (IRAK4L)

1. Lee et al. Sci Rep. 2017; 7: 1785. 2. https://www.lls.org/sites/default/files/file assets/waldenstrommacroglobulinemia.pdf 3. https://seer.cancer.gov/statfacts/html/dlbcl.html.

4. Varettoni et al. Blood (2013) 121 (13): 2522-2528. 5. Hattori et al. Cancer Sci. 2018 Jan; 109(1): 225-230.


Degradation of IRAK4, Ikaros and Aiolos Correlates to Cell Killing



- IRAK4, Ikaros and Aiolos degradation measured in MYD-88-mutated OCI-Ly10 cells after 24 h of drug exposure
 - IRAK4 $DC_{50} = 4 \text{ nM}$
 - Ikaros/Aiolos $DC_{50} = 2/2 \text{ nM}$

• Degradation correlates with cell killing effects


• $IC_{50} = 31 \, nM$



IRAKIMiD Degrader Concentration (µM)


KT-413 is Highly Active on Intermittent Dosing Regimens and Superior to Clinically Active CA-4948 and CC-220

- In the OCI-Ly10 MYD88^{MT} xenograft model, intermittent dosing of KT-413 induced strong antitumor activity, including complete or partial regressions
 - Superior activity compared to the clinically active IRAK4-inhibitor CA-4948 or the latest generation IMiD CC-220 alone
- Minimally active dose of 3 mg/kg D1,2 showed extended tumor exposure and strong degradation of both IRAK4 and IMiD substrates that was maintained for at least 72h



Drug	CR	PR	SD	PD
CA-4948	0	0	3	4
CC-220	0	1	4	2
KT-413 (5 mpk)	2	2	3	-
KT-413 (10 mpk)	5	2	-	-

CR: <10mm³ tumor on D26 PR: >50% regression from baseline SD: <50% regression to 20% increase in tumor volume PD: >20% tumor growth on D26



KT-413 Shows Regressions in MYD88^{MT} Patient-Derived Xenograft Models

Model	MYD88	CD79B	TNFAIP3	Other	KT-413 (%TGI)
LY14019	L265P	MT	MT		100
LY2264	L265P	MT		IRF4	100
LY2298	L265P	MT		BCL2/BCL6	90
LY12699	L265P	MT			87
LY2345	WT		MT		70
LY2301	WT				30
LY0257	L265P			BCL2/BCL6/IKZF3	0

KT-413 dosed orally shows strong tumor growth inhibition (>85% TGI) in 4/5 MYD88-Mutated DLBCL PDX Models


- Activity is observed regardless of co-mutations that activate NFkB and IRF4 pathways
- The non-responsive MYD88^{MT} model LY0257 harbors a mutation in Aiolos and is reported to be insensitive to lenalidomide
- The functional consequence of Aiolos mutations in IRAKIMiD and IMiD response is being investigated

Some level of tumor growth inhibition observed in MYD88-WT PDX

• May be consistent with IMiD activity of KT-413

©2021 KYMERA THERAPEUTICS, INC.

KYMERA




PDX models run at Crown Biosciences

KT-413 has Synergistic Activity in Driving Deep Tumor Regressions in Combination with Other Therapies in Preclinical Models


 KT-413 administered on intermittent schedules demonstrated deep and durable regressions in combination with rituximab in MYD88MT OCI-Ly10 xenografts

Tumor Volume (mm³)

 KT-413 + rituximab showed strong tumor regressions in tumors that relapsed following initial R-CHOP treatment



KT-413 Development Plan



- Multi-center Phase 1 dose escalation study (US sites) start in 2H21
- Relapsed/refractory B cell lymphomas, including MYD88-mutant DLBCL
- Objectives include safety, tolerability, PK and PD (proof-of-biology) and preliminary clinical activity
- Clinical and biomarker endpoints
- POB to be presented in 2022

- Phase 1b expansion cohorts in DLBCL (MYD88mut and -wt) and other MYD88-mut lymphomas, including Waldenstrom's macroglobulinemia and primary central nervous system lymphoma
- Objectives include safety, tolerability and clinical activity of monotherapy and select combinations
- Clinical and biomarker endpoints
- Potential expansion in other indications






STAT3 Biology and Degrader Rationale

- STAT3 is a traditionally largely undrugged transcription factor activated through cytokine and growth factor receptors via JAKs and non-JAKs mediated mechanisms
- High degree of validation of JAK-STAT pathway in oncology and immuno-oncology supported also by numerous publications
- STAT3 plays a role in tumor biology, evasion of immune surveillance and inflammation/fibrosis
- No known drugs specifically affect STAT3 broadly across all relevant cell types

Indications/Expected Timeline

Hematological Malignancies/Solid Tumors and <u>Autoimmune/Fibrosis</u> Nomination of development candidate: 1Q 2021 ✓ IND/Phase 1 initiation: 4Q 2021 Phase 1 proof-of-biology in patients: 2022



STAT3 Opportunity in Oncology & Autoimmunity

First-in-class opportunity to address STAT3-driven pathology across large and diverse indications

Tumors


Liquid .

Solid Tumors

Autoimmune

Fibrosis

Patient Impact (U.S.)



©2021 KYMERA THERAPEUTICS, INC.

Genetically-defined STAT3 mutation and/or hyperactivation PTCL, CTCL, T-LGL leukemia

STAT3 activation and dependency DLBCL, AML, multiple myeloma

Cell Intrinsic: STAT3 role in EMT/TKI resistance Combinations in TKI / chemotherapy resistant settings

Cell Extrinsic: STAT3 role in IO T-cell infiltrated tumors. Combinations with immune-modulators

STAT3 GOF syndrome

Genetically-defined population characterized by enteropathy, arthritis, dermatitis, lung disease

Immune-inflammatory

Systemic sclerosis, atopic dermatitis, rheumatoid arthritis, Crohn's disease/ulcerative colitis

Chronic inflammation / fibrosis

Idiopathic pulmonary fibrosis, CKD/renal fibrosis


1. Marchi and O'Connor, CA CANCER J CLIN 2020;70:47-70. 2. Criscione and Weinstock. Arch Dermatol. 2007 Jul:143(7):854-9. 3. https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html.

KYMERA

Cancer

|/|


KT-333 Highly Specific Degradation of STAT3



Full and Durable Regressions Across Multiple in vivo Preclinical Tumor Models

 Mice bearing STAT3-dependent ALK+ ALCL SU-DHL-1 (above) and STAT3-driven ALK+ ALCL xenograft model SUP-M2 (below) tumors dosed with STAT3 degrader

- Dose and degradation dependent tumor growth inhibition observed with once-aweek IV dosing
- 30 mg/kg sufficient to drive full tumor regression that was durable for multiple weeks after the last dose



-iquid Tumors


CANCER

STAT3 Degrader *In Vivo* Active in Preclinical PD-1/L-1 Refractory Solid Tumor Model

CANCER

Solid Tumors

- Kymera's STAT3 degrader assessed in colorectal cancers (CT-26) known to be refractory to approved immunotherapies
- STAT3 degrader significantly reduced tumor growth when administered every two days
- Analysis of tumors showed synergistic modulation of immune cells (M2/M1 and T cells) within the tumor microenvironment to favor an anti-tumor response



Macrophages (M1/M2)

STAT3 Degrader Development Plan in Liquid & Solid Tumors



- Multi-center Phase 1 dose escalation study start in 4Q21
- Safety, tolerability, PK and PD (proof-of-biology) and preliminary clinical activity
- Clinical and biomarker endpoints
- POB to be presented in 2022

- Phase 1b expansion cohorts in STAT3-dependent liquid tumors
- Objectives include safety, tolerability and clinical activity of monotherapy and select combinations
- Separate Phase 2 in solid tumors





investors@kymeratx.com

media@kymeratx.com

inquiries@kymeratx.com

